Posts Tagged ‘drug shortages’

Semaglutide Cuts Kidney Failure and Death in Diabetes

May 25, 2024 — We’ve been waiting for this. Back in October, headlines flashed the news that Novo Nordisk had stopped a big outcomes study of semaglutide and its effect on kidney failure and death. They stopped it because it had worked so well. Continuing to give a placebo to half the people in the study would have been […]

Disrupting the Obesity Status Quo Is Exquisitely Uncomfortable

May 5, 2024 — “Drug compounding with semaglutide and tirzepatide is a public health emergency,” said a respected obesity medicine physician to us this week. They were right. Most of the compounded drugs people encounter when they are desperate to obtain these life-changing medicines are sketchy at best. This week, FDA announced the arrest of a TikToker for selling […]

From Boom to Bust in Compounded GLP-1 Medicines

January 16, 2024 — If you wonder why the Obesity Action Coalition, Obesity Medicine Association, and the Obesity Society all warn against using compounded versions of GLP-1 medicines for obesity, consider the boom and bust story of ACA Pharmacy in Nashville, Tennessee. After semaglutide went into shortage in 2022, it began doing a booming business with a compounded version […]

Buyer Beware: Compounded and Fake Semaglutide

January 9, 2024 — Unfortunately, we are facing the new year with a great demand for advanced new obesity medicines and an inadequate supply. On the FDA drug shortages website, all strengths of the Wegovy brand, except 2.4 mg, have limited availability. Both Wegovy and Ozempic are “currently in shortage.” This opens the door for compounded semaglutide and a […]

The Best and Worst of 2023 in Obesity and Health

December 28, 2023 — This was a year of great progress in obesity, and with that progress came frustrations and angst. So finding the best and worst of 2023 in obesity and health is actually quite an easy and interesting task. Let’s dig right in. #1 Best: Cardiovascular Outcomes Benefit Data for Semaglutide Above all else the landmark findings […]

Compounding, Biosimilars, Generics, and the Semaglutide Supply

October 30, 2023 — It leaves our heads spinning. Normal healthcare systems cannot keep up with the demand for a breakthrough in obesity treatment. The company, Novo Nordisk, which developed semaglutide for obesity treatment, has invested billions and now is reaping many billions of dollars in sales. But despite more than a decade of preparation, they can’t keep up. […]

GLP-1 Medicines: Constrained Supply, High Prices, Low Access

July 1, 2023 — The news arrived in our inbox yesterday. Drug shortages that have plagued semaglutide and tirzepatide are growing worse, not fading. Novo Nordisk quietly let the word out: those supply shortages are no longer limited to Ozempic and Wegovy. Saxenda is entering a prolonged period of shortage. So it now appears that constrained supply, high prices, […]

Cheap Copies of Semaglutide Under Scrutiny

May 8, 2023 — Semaglutide for the treatment of obesity continues to be in short supply. Late last week, Novo Nordisk announced that, because the company is still having difficulty keeping up with demand, they would limit production of the lower doses used to start patients on Wegovy. Thus, compounding pharmacies are selling cheap copies of semaglutide injection and […]